ArchiMed, an investment management firm, agreed to acquire Stragen Pharma, a developer of hard-to-make, complex generic drugs for the treatment of patients with life-threatening conditions. Financial terms were not disclosed. “ArchiMed knows our market inside and out. With their backing, Stragen will have the means and freedom to pursue growth," Jean-Luc Tétard, Stragen Pharma Founder and CEO.